The Lysosomal Storage Disease Drug market is a subset of the Endocrine and Metabolic Disorders Drugs market. These drugs are used to treat lysosomal storage diseases, which are a group of inherited metabolic disorders caused by the deficiency of lysosomal enzymes. These drugs are used to replace the missing enzymes, allowing the body to break down and recycle certain molecules. They can also be used to reduce the accumulation of toxic substances in the body. The Lysosomal Storage Disease Drug market is highly competitive, with many companies developing and marketing drugs for these disorders. Some of the major players in the market include Sanofi, Pfizer, Shire, and Alexion Pharmaceuticals. Other companies such as Amicus Therapeutics, Ultragenyx Pharmaceutical, and Protalix BioTherapeutics are also actively involved in the development of drugs for lysosomal storage diseases. Show Less Read more
ASK A QUESTION
We request your telephone number so we can contact you in the event we have difficulty reaching you via email. We aim to respond to all questions on the same business day.
